Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Washington Fred Hutchinson Cancer Research Center |
---|---|
Information provided by: | University of Washington |
ClinicalTrials.gov Identifier: | NCT00234299 |
Aspirin affects many physiological processes through its anti-inflammatory actions. Various cancers, including prostate cancer, appear to utilize inflammatory signals to facilitate their growth and progression.
We hypothesize that oral aspirin acts directly on prostate epithelial cells to alter COX-2-related metabolism and inhibit prostate cell growth.
Condition | Intervention |
---|---|
Prostate Cancer |
Drug: Aspirin Drug: Placebo |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study |
Official Title: | In Vivo Molecular Effects of Aspirin on Prostate Tissue |
Estimated Enrollment: | 60 |
Study Start Date: | December 2005 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Group A: Active Comparator
Enteric coated aspirin 325mg, one tablet orally every day for six months prior to prostate biopsy.
|
Drug: Aspirin
325mg, one tablet orally, six months
|
Group B: Placebo Comparator
Enteric coated placebo, one tablet orally every day for six months prior to prostate biopsy.
|
Drug: Placebo
325mg, one tablet orally every day, 6 months
|
Prostate cancer is the most common non-cutaneous malignancy in men and is the second leading cause of cancer death among U.S. men. 221,000 new cases and 29,000 deaths are expected in 2003. The incidence of prostate cancer diagnosis is increasing at 3% per year. Prostate specific antigen (PSA) screening has resulted in improvements in early diagnosis of prostate cancer. However, available treatments all may have a significant negative effect on quality of life.
Studies have implicated a beneficial association between ASA use and a lower risk of other types of malignancies, including stomach, esophageal, breast, ovarian, and prostate cancer. There is significant evidence to suggest that aspirin has a protective effect against prostate cancer.
Ages Eligible for Study: | 45 Years to 74 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Daniel W Lin, MD | 206-764-2265 | dlin@u.washington.edu |
Contact: Crystal A Kimmie, BS | 206-277-5598 | crystal.kimmie@va.gov |
United States, Washington | |
VA Puget Sound Health Care Service | Recruiting |
Seattle, Washington, United States, 98108 | |
Contact: Daniel W Lin, MD 206-764-2265 dlin@u.washington.edu | |
Contact: Crystal A Kimmie, BS 206-277-5598 crystal.kimmie@va.gov | |
Principal Investigator: Daniel W Lin, MD |
Principal Investigator: | Daniel W Lin, MD | Veteran's Administration Puget Sound Health Care Service |
Responsible Party: | Fred Hutchinson Cancer Research Center / University of Washington / VA Puget Sound HCS ( Daniel W. Lin, MD / Principal Investigator ) |
Study ID Numbers: | 05-7956-01 |
Study First Received: | October 4, 2005 |
Last Updated: | November 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00234299 |
Health Authority: | United States: Institutional Review Board |
Cancer Prostate Preventive Therapy |
Aspirin Prostatic Diseases Genital Neoplasms, Male |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Cyclooxygenase Inhibitors Hematologic Agents Physiological Effects of Drugs Enzyme Inhibitors Fibrinolytic Agents Cardiovascular Agents Pharmacologic Actions Fibrin Modulating Agents Neoplasms |
Neoplasms by Site Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Platelet Aggregation Inhibitors Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |